Vegfr2. The Vascular Endothelial Growth Factor 2 is a receptor of tyrosine kinases that have been implicated in tumor angiogenesis, a key feature of many cancers . However, the number of drugs for cancer treatments targeting Vegfr2 are limited . Sorafenib is the main reference ligand as an oral multi-target kinase inhibitor of tumor genesis and angiogenesis. In particular cases, Sorafenib binds Vegfr2 and prolonged survival times of chemotherapy-resistant patients. Although some docking explorations have been published , no Vegfr2 was yet targeted by DW-BEL.